Literature DB >> 11123039

Dehydroepiandrosterone and biologics in the treatment of systemic lupus erythematosus.

R Furie1.   

Abstract

Our understanding of the immune system in health and disease has greatly increased over this past decade. An outgrowth of this burgeoning knowledge has been the discovery of novel strategies to treat a variety of autoimmune diseases. As a result, significant advances have been made in the treatment of arthritis with a half-dozen new treatments approved between September, 1998 and November, 1999. Although no new therapies have been approved for the treatment of systemic lupus erythematosus (SLE), this decade has witnessed an unprecedented amount of activity in drug development for this disease. This article specifically addresses the current status of drug development in the area of hormonal and biologic therapies for SLE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123039     DOI: 10.1007/s11926-996-0068-5

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  30 in total

1.  CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris.

Authors:  J R Abrams; M G Lebwohl; C A Guzzo; B V Jegasothy; M T Goldfarb; B S Goffe; A Menter; N J Lowe; G Krueger; M J Brown; R S Weiner; M J Birkhofer; G L Warner; K K Berry; P S Linsley; J G Krueger; H D Ochs; S L Kelley; S Kang
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Reduction in circulating dsDNA antibody titer after administration of LJP 394.

Authors:  M H Weisman; H G Bluestein; C M Berner; H A de Haan
Journal:  J Rheumatol       Date:  1997-02       Impact factor: 4.666

3.  Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.

Authors:  R F van Vollenhoven; L M Morabito; E G Engleman; J L McGuire
Journal:  J Rheumatol       Date:  1998-02       Impact factor: 4.666

4.  Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG.

Authors:  F Silvestris; O D'Amore; P Cafforio; L Savino; F Dammacco
Journal:  Clin Exp Immunol       Date:  1996-05       Impact factor: 4.330

5.  C1q: a multifunctional ligand for a new immunoadsorption treatment.

Authors:  F Hiepe; B Pfüller; K Wolbart; A Bruns; H P Leinenbach; M Hepper; W Schössler; V Otto
Journal:  Ther Apher       Date:  1999-08

6.  Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

Authors:  Y Wang; Q Hu; J A Madri; S A Rollins; A Chodera; L A Matis
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

7.  A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.

Authors:  R F van Vollenhoven; J L Park; M C Genovese; J P West; J L McGuire
Journal:  Lupus       Date:  1999       Impact factor: 2.911

8.  Low sulpho-conjugated steroid hormone levels in systemic lupus erythematosus (SLE).

Authors:  M Hedman; E Nilsson; B de la Torre
Journal:  Clin Exp Rheumatol       Date:  1989 Nov-Dec       Impact factor: 4.473

Review 9.  Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus.

Authors:  R H Derksen
Journal:  Semin Arthritis Rheum       Date:  1998-06       Impact factor: 5.532

10.  Treatment of murine lupus with CTLA4Ig.

Authors:  B K Finck; P S Linsley; D Wofsy
Journal:  Science       Date:  1994-08-26       Impact factor: 47.728

View more
  2 in total

1.  Sex-related differences in urinary immune-related metabolic profiling of alopecia areata patients.

Authors:  Yu Ra Lee; Haksoon Kim; Bark Lynn Lew; Woo Young Sim; Jeongae Lee; Han Bin Oh; Jongki Hong; Bong Chul Chung
Journal:  Metabolomics       Date:  2020-01-16       Impact factor: 4.290

Review 2.  Sex Hormones in Acquired Immunity and Autoimmune Disease.

Authors:  Vaishali R Moulton
Journal:  Front Immunol       Date:  2018-10-04       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.